Ublituximab

WEST PALM BEACH, Fla. — Real-world effects of ublituximab after 1 year of administration were consistent with data from a pair of phase 3 clinical trials investigating the drug, according to a poster presented at ACTRIMS.

Time-limited dual B-cell receptor inhibitor therapy with acalabrutinib, umbralisib and ublituximab showed potential in treatment-naive and relapsed/refractory chronic lymphocytic leukemia, according to data presented at ASH Annual Meeting.

Treatment with ublituximab suppressed new lesion formations after 1 year while reducing thalamic volume loss and increasing T1 hypointense lesion volume compared with teriflunomide, according to data presented at ECTRIMS 2023.

In this edition, risk factors linked to PD, digital brain health platform offers dementia risk assessment, Klotho protein levels linked to Alzheimer's and more.

The combination of umbralisib and ublituximab demonstrated superior PFS and overall response rates compared with chemoimmunotherapy among patients with chronic lymphocytic leukemia and Bruton tyrosine kinase inhibitor risk factors.

The combination of umbralisib and ublituximab significantly improved PFS compared with chemoimmunotherapy for patients with chronic lymphocytic leukemia, according to study results presented at the virtual ASH Annual Meeting and Exposition.

Ublituximab, an anti-CD20 monoclonal antibody, resulted in a statistically significant decrease in annualized relapse rates among patients with relapsing forms of MS in the ULTIMATE I and ULTIMATE II studies, according to a press release.

The FDA granted fast track designation to the combination of ublituximab and umbralisib for the treatment of adults with chronic lymphocytic leukemia, according to a press release from the drugs’ manufacturer.